Tiziana Life Sciences Gets $3.4 Million in Funding for Neurodegenerative Disease Studies
Tiziana Life Sciences (TLSA) said Friday it secured $3.4 million in nondilutive funding to support its phase 2 trial of intranasal foralumab in nonactive secondary progressive multiple sclerosis and a
Express News | Tiziana Receives $3.4 Million in Non-Dilutive Funding
Press Release: Tiziana Receives $3.4 Million in Non-Dilutive Funding
Tiziana Receives $3.4 Million in Non-Dilutive Funding NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company deve
Express News | Tiziana Life Sciences Ltd: To Dose First Patient With Moderate Alzheimer's Disease With Foralumab
Express News | Tiziana Life Sciences: FDA Has Allowed Intranasal Foralumab to Be Used Under Expanded Access Ind in First Patient With Moderate Alzheimer S Disease
Tiziana Life Sciences to Dose First Patient With Moderate Alzheimer's Disease With Foralumab
NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug
Social Buzz: Wallstreetbets Stocks Mixed Premarket Monday; Nvidia to Decline, Micron Technology to Open Higher
The most-talked-about stocks in the Reddit subforum Wallstreetbets were mixed hours before Monday's opening bell. Nvidia (NVDA) fell by 2.4% in premarket hours, declining further after closing Friday
12 Health Care Stocks Moving In Monday's After-Market Session
GainersASLAN Pharma (NASDAQ:ASLN) shares moved upwards by 11.9% to $0.4 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Biora Therapeutics (NASDA
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
Tiziana Multiple Sclerosis Asset Foralumab Fast Track Application Accepted
Tiziana Life Sciences Receives FDA Acceptance For Fast Track Designation Submission Of Intranasal Foralumab For Treating Non-Active Secondary-Progressive Multiple Sclerosis (Na-SPMS)
Tiziana Life Sciences Receives FDA Acceptance For Fast Track Designation Submission Of Intranasal Foralumab For Treating Non-Active Secondary-Progressive Multiple Sclerosis (Na-SPMS)
Express News | FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
Tiziana Life Sciences Seeks FDA Fast Track Designation for Foralumab in MS Treatment | NASDAQ:TLSA
12 Health Care Stocks Moving In Friday's After-Market Session
GainersAnitra (AMEX:AZTR) stock rose 17.0% to $0.17 during Friday's after-market session. The company's market cap stands at $5.0 million. Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 12
Tiziana Life Sciences Reports Six-Month Qualitative Results For All 10 Non-Active Secondary Progressive Multiple Sclerosis Patients Enrolled In Intermediate-Size Patient Population Expanded Access Program
Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access patients receiving intranasal foralumab for at least 6-months.FDA A
Express News | Tiziana Life Sciences has applied to FDA for orphan drug designation for Foralumab to treat NA-Spms.
Express News | Tiziana Life Sciences Ltd: Applied for FDA Orphan Drug Designation of Foralumab for NA-Spms
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access patients receiving intranasal foralumab for at least 6-months.FDA Allowance for an
Tiziana Life Sciences Reports Qualitative Improvement in MS Patients Treated With Lead Asset | NASDAQ:TLSA
Express News | Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab